Indeed, hypoxia and increased expression of hypoxia-inducible factor 1α (HIF-1α), the key transcription factor mediating hypoxia response, are associated with endocrine resistance to neoadjuvant and adjuvant therapy in ERα+ breast cancers (7, –9). This evidence concerns the gene HIF1A and breast carcinoma.